


An Alternative Synthesis of the Enantiomerically Pure Competitive NMDA Antagonists SDZ 220-581 and SDZ EAB 515

by Werner Müller*, Markus Bänziger, and Peter Kipfer

Novartis Pharma AG, CH-4002 Basel

An alternative synthesis of enantiomerically pure SDZ 220-881 (**1a**) and SDZ EAB 515 (**1b**) starting from L-Z-tyrosine is described.

Introduction. – Biphenyl analogues of AP7 ((2*R*)-2-amino-7-phosphonoheptanoic acid) such as SDZ 220-581 (**1a**) and SDZ EAB 515 (**1b**) are selective competitive NMDA antagonists with high affinities for the NMDA recognition site *in vitro* [1][2] and with corresponding *in vivo* activities in various animal models [3]. Recently [1], we published a synthesis of enantiomerically pure SDZ EAB 515 (**1b**) and its substituted analogues by employing the chiral glycine derivative **3** (Scheme 1) [4]. We describe here an alternative synthesis of such compounds by starting from the readily available L-Z-tyrosine.




Results and Discussion. – Compounds of type **1** are 3,5-disubstituted L-phenylalanines (Scheme 1). Retrosynthetic analysis towards introduction of the CH₂OH and Br substituents at C(3) and C(5) of the phenylalanine by electrophilic substitution reactions leads to L-tyrosine as possible starting material. In fact, the phenolic OH group in the L-tyrosine molecule activates the *ortho*-positions in the Ph ring and directs the CH₂OH and the Br substituent into the desired positions. As outlined in Scheme 2, hydroxymethylation of

L-Z-tyrosine with a mixture of formaline, NaOH, and borax as a complex builder at 40° for 4 days, followed by bromination in AcOH and then esterification gave the crystalline intermediate **9** in 68% yield over three steps.

The cyclic dimethyl-ketal group of diol **9** proved to be a suitable protecting group for the conditions of standard *Suzuki* cross coupling. Reaction of the crystalline bromo derivative **10** with, e.g., 2-chlorobenzeneboronic acid in the presence of catalytic amounts of Pd(OAc)₂ and PPh₃, followed by simultaneous cleavage of the acetal protecting group and selective acetylation of the benzylic alcohol function, gave **11a** with a yield of 33% over three steps.

Scheme 2



To remove the directing phenolic functional group, we used the method of Pd⁰-catalyzed deoxygenation of phenol triflate [5]. Thus, phenols **11a** and **11b** were treated with (CF₃SO₂)₂O and EtN(i-Pr)₂ in dry CH₂Cl₂ at –50° and the corresponding trifluoromethanesulfonates **12a** and **12b** reduced with triethylammonium formate and 1,3-bis(diphenylphosphino)propane (dppp). This bidentate phosphine ligand has been described to be especially useful for sterically hindered phenols [6]. Transesterification (MeOH/H⁺) followed by treatment of the resulting benzyl alcohol with BBr₃ led to bromides **14a** and **14b** in good overall yields (37 and 71%, resp., over three steps).

The phosphonates **15a** and **15b** were prepared by treating the corresponding bromides **14a** and **14b** with dimethyl and dibutyl phosphite, respectively, in toluene with potassium bis(trimethylsilyl)amide as base and 18-crown-6 at 0° (*Michaelis-Becker* reaction), followed by chromatography of the reaction mixture over silica gel. Hydrolysis (aq. HBr in AcOH) and crystallization from THF/aq. HCl led to amino diacids **1a** and **1b**, respectively, in good yields. The free amino diacids (*S*)-**1** proved to be identical to the product obtained by the former synthetic pathway [1] and enantiomerically pure by analysis on *Chiralplate*[®] TLC (see *Exper. Part*) and on capillary electrophoresis.

Experimental Part

General. EtN(i-Pr)₂ was dried over molecular sieves (4 Å). All other commercially available chemicals were used as provided by the supplier without purification. TLC: silica gel 60 *F-254* from *Merck*; *Chiralplate*[®] from *Macherey-Nagel* (amino acid dissolved in 2M NH₃ and detected with a 0.1% soln. of ninhydrin in EtOH). Column chromatography: silica gel 60 (230–400 mesh) from *Merck* at medium pressure. M.p.: *Reichert* hot stage; uncorrected. Optical rotations: *Perkin-Elmer 241* polarimeter; cell length 10 cm. ¹H-NMR Spectra: *Varian Gemini-200*, 200 MHz spectrometer, CDCl₃ solns., unless otherwise stated; δ in ppm with TMS as standard, coupling constants *J* in Hz. The enantiomeric purity (% ee) were determined by capillary electrophoresis (UV detector, area under the curve).

N-(*Benzoyloxycarbonyl*)-3-(*hydroxymethyl*)-*L*-tyrosine (**8**) [7]. A mixture of *N*-(*benzyloxycarbonyl*)-*L*-tyrosine (**7**; 25.0 g, 79 mmol), Na₂B₄O₇ · 10 H₂O (65 g), formaline (37% aq. CH₂O soln.; 25 ml, 330 mmol), 1M aq. NaOH (156 ml, 156 mmol), and H₂O (450 ml) was stirred for 120 h at 40°. The pH of the mixture was adjusted to 2 with 10% HCl and extracted with AcO(i-Pr). The org. layer was dried (Na₂SO₄) and evaporated to give **8** (26.7 g) as an oil, which was used without further purification for the next reaction. ¹H-NMR: 2.75 (*m*, 1 H); 2.95 (*m*, 1 H); 3.4 (*br. s*, 1 H); 4.1 (*m*, 1 H); 4.43 (*s*, 2 H); 4.95 (*s*, 2 H); 6.7 (*d*, *J* = 7, 1 H); 6.95 (*d*, *J* = 7, 1 H); 7.2 (*s*, 1 H); 7.3 (*s*, 5 H); 7.6 (*d*, *J* = 7, 1 H); 9.2 (*s*, 1 H); 12.6 (*br. s*, 1 H).

N-(*Benzoyloxycarbonyl*)-3-bromo-5-(*hydroxymethyl*)-*L*-tyrosine Methyl Ester (**9**). To a soln. of **8** (26.6 g, max. 79 mmol) and NaOAc (6.65 g, 81 mmol) in AcOH (300 ml), Br₂ (4.05 ml, 79 mmol) was added dropwise with stirring at 10° within 5 min. After stirring at 15° for 30 min, the mixture was evaporated. The residue was partitioned between ice/H₂O and AcO(i-Pr). The org. phase was dried (Na₂SO₄) and evaporated. A soln. of this residue (37.2 g) and TsOH (0.7 g) in 280 ml of MeOH was stirred under reflux for 3 h. The mixture was evaporated. The residue treated with 10% aq. KHCO₃ soln. and extracted with AcO(i-Pr). The org. layer was dried (Na₂SO₄), evaporated, and the residue (33 g) was crystallized from cyclohexane/AcOEt 2:1 to afford **9** (23.5 g, 68% over 3 steps). M.p. 97–100°. ¹H-NMR ((D₆)DMSO): 2.1 (*s*, 2 H); 2.75 (*m*, 1 H); 2.92 (*m*, 1 H); 3.62 (*s*, 3 H); 4.18 (*m*, 1 H); 4.52 (*s*, 2 H); 5.0 (*s*, 2 H); 7.3 (*m*, 7 H); 7.8 (*d*, *J* = 14, 1 H). Anal. calc. for C₁₉H₂₀BrNO₆ (438.27): C 52.07, H 4.58, Br 18.23, N 3.20; found: C 52.30, H 4.60, Br 17.70, N 3.30.

(*S*)-Methyl 2-[(*Benzoyloxycarbonyl*)amino]-3-(8-bromo-2,2-dimethyl-4H-1,3-benzodioxin-6-yl)propanoate (**10**). A soln. of **9** (16.3 g, 37.2 mmol), acetone dimethyl acetal (9.4 ml, 76.7 mmol), and TsOH (0.4 g) in 200 ml of THF was stirred at 55° for 4.5 h. The mixture was evaporated, the residue treated with 10% aq. KHCO₃ soln. and extracted with AcO(i-Pr). The org. layer was dried (Na₂SO₄), evaporated, and the residue (17.4 g) was crystallized from cyclohexane/AcOEt 3:1 to afford 15.9 g (89%) of **10**. M.p. 87–90°. ¹H-NMR ((D₆)DMSO): 1.5 (*s*, 6 H); 2.8 (*m*, 1 H); 2.95 (*m*, 1 H); 3.65 (*s*, 3 H); 4.25 (*m*, 1 H); 4.78 (*s*, 2 H); 5.0 (*m*, 2 H); 6.95 (*s*, 1 H); 7.35 (*m*, 6 H); 7.85 (*d*, *J* = 14, 1 H). Anal. calc. for C₂₂H₂₄BrNO₆ (478.34): C 55.24, H 5.06, Br 16.70, N 2.93, O 20.07; found: C 55.12, H 4.97, Br 16.80, N 3.11, O 19.90.

(*S*)-Methyl 3-[5-(Acetoxymethyl)-2'-chloro-6-hydroxy-1,1'-biphenyl-3-yl]-2-[(benzyloxycarbonyl)amino]propanoate (**11a**). A soln. of **10** (12.0 g, 25.0 mmol), 2-chlorobenzeneboronic acid (4.7 g, 30.0 mmol), 2M aq. Na₂CO₃ soln. (29 ml), and EtOH (4 ml) in toluene (360 ml) was degassed in an ultrasonic bath and flushed with Ar before Pd(OAc)₂ (0.3 g) and PPh₃ (0.7 g) were added. The mixture was stirred at reflux under Ar for 2 h. After addition of charcoal, the mixture was filtered and the filtrate extracted with AcO(*i*-Pr). The org. layer was dried (Na₂SO₄) and evaporated. A soln. of this residue (15.2 g) and TsOH (0.17 g) in 80 ml of AcOH was stirred at 70° for 3 h. The mixture was evaporated, the residue treated with 10% aq. KHCO₃ soln., and extracted with AcO(*i*-Pr). The org. layer was dried (Na₂SO₄) and evaporated to give **11a** (4.2 g, 33% over 3 steps). Oil. ¹H-NMR ((D₆)DMSO): 2.1 (s, 3 H); 2.8 (m, 1 H); 2.98 (m, 1 H); 3.65 (s, 3 H); 4.25 (m, 1 H); 5.0 (s, 2 H); 5.1 (s, 2 H); 6.95 (s, 1 H); 7.16 (s, 1 H); 7.35 (m, 8 H); 7.52 (m, 1 H); 7.82 (d, *J* = 14, 1 H); 8.65 (s, 1 H).

(*S*)-Methyl 3-[5-(Acetoxymethyl)-6-hydroxy-1,1'-biphenyl-3-yl]-2-[(benzyloxycarbonyl)amino]propanoate (**11b**). As described for **11a** with 3.7 g (7.7 mmol) of **10** and 1.1 g (9.0 mmol) of benzeneboronic acid: 1.7 g (46%) of **11b**. ¹H-NMR ((D₆)DMSO): 2.05 (s, 3 H); 2.84 (m, 1 H); 3.0 (m, 1 H); 3.65 (s, 3 H); 4.25 (m, 1 H); 5.0 (s, 2 H); 5.1 (s, 2 H); 7.15 (s, 2 H); 7.3–7.54 (m, 9 H); 7.85 (d, *J* = 14, 1 H); 8.6 (s, 1 H).

(*S*)-Methyl 3-[5-(Acetoxymethyl)-2'-chloro-6-[(trifluoromethyl)sulfonyl]-1,1'-biphenyl-3-yl]-2-[(benzyloxycarbonyl)amino]propanoate (**12a**). To a stirred soln. of **11a** (5.4 g, 10.5 mmol) in EtN(*i*-Pr)₂ (2.2 ml, 13 mmol) and abs. CH₂Cl₂ (55 ml), (CF₃SO₂)₂O (2.15 ml, 13 mmol) was added dropwise at ca. –65° over 5 min. Stirring was continued at ca. –55° for 1 h. After addition of ice/sat. aq. KHCO₃ soln., the mixture was extracted with AcO(*i*-Pr). The org. layer was dried (Na₂SO₄) and evaporated. A soln. of this residue (7.7 g) in cyclohexane/AcOEt 2:1 was purified by adding silica gel and charcoal. The filtrate was evaporated to give **12a** (6.9 g). Oil. ¹H-NMR ((D₆)DMSO): 2.0 (s, 3 H); 2.92 (m, 1 H); 3.18 (m, 1 H); 3.62 (s, 3 H); 4.35 (m, 1 H); 4.92 (s, 2 H); 5.1 (s, 2 H); 7.2–7.55 (m, 9 H); 7.6 (s, 2 H); 7.9 (d, *J* = 14, 1 H).

(*S*)-Methyl 3-[5-(Acetoxymethyl)-6-[(trifluoromethyl)sulfonyl]-1,1'-biphenyl-3-yl]-2-[(benzyloxycarbonyl)amino]propanoate (**12b**). As described for **12a** with 1.7 g (3.5 mmol) of **5b** and (CF₃SO₂)₂O (0.7 ml, 4.2 mmol): 2.2 g of **12b**. Oil. ¹H-NMR ((D₆)DMSO): 2.1 (s, 3 H); 2.95 (m, 1 H); 3.15 (m, 1 H); 3.65 (s, 3 H); 4.4 (m, 1 H); 4.95 (s, 2 H); 5.15 (s, 2 H); 7.3 (s, 5 H); 7.55 (s, 4 H); 7.5 (s, 2 H); 7.9 (d, *J* = 14, 1 H).

(*S*)-Methyl 3-[5-(Acetoxymethyl)-2'-chloro-1,1'-biphenyl-3-yl]-2-[(benzyloxycarbonyl)amino]propanoate (**13a**). A stirred mixture of **12a** (48.3 g, 75 mmol), LiCl (3.1 g), Et₃N (200 ml, 1.48 mol), and DMF (500 ml) was flushed with Ar and cooled below 15° before HCOOH (56 ml, 1.48 mol) was added dropwise. After addition of Pd(OAc)₂ (1.7 g, 7.5 mmol) and 1,3-bis(diphenylphosphino)propane (3.1 g, 7.5 mmol), stirring was continued at ca. 60° under Ar. After 4 h, the soln. was evaporated and the residue partitioned between H₂O and AcO(*i*-Pr). The org. layer was washed with 10% aq. NH₄Cl soln. and 10% aq. KHCO₃ soln., dried (Na₂SO₄), and evaporated to give **13a** (41.9 g). Oil. ¹H-NMR: 2.1 (s, 3 H); 3.18 (d, 2 H); 3.72 (s, 3 H); 4.7 (m, 1 H); 5.1 (s, 4 H); 5.3 (m, 1 H); 7.14 (d, *J* = 14, 2 H); 7.2–7.5 (m, 10 H).

(*S*)-Methyl 3-[5-(Acetoxymethyl)-1,1'-biphenyl-3-yl]-2-[(benzyloxycarbonyl)amino]propanoate (**13b**). As described for **13a** with 1.6 g (2.6 mmol) of **12b**, LiCl (130 mg), Et₃N (8.0 ml, 57 mmol), DMF (22 ml), HCOOH (2.2 ml, 57 mmol), Pd(OAc)₂ (0.44 g), and 1,3-bis(diphenylphosphino)propane (0.78 g): 1.4 g of **13b**. Oil. ¹H-NMR: 2.1 (s, 3 H); 3.2 (m, 2 H); 3.75 (s, 3 H); 4.7 (m, 1 H); 5.1 (s, 4 H); 5.25 (m, 1 H); 7.2–7.6 (m, 13 H).

(*S*)-Methyl 2-[(Benzyloxycarbonyl)amino]-3-[5-(bromomethyl)-2'-chloro-1,1'-biphenyl-3-yl]propanoate (**14a**). A soln. of **13a** (41.9 g) in MeOH (350 ml) and conc. HCl (4.0 ml) was stirred at ca. 65°. After 2 h, the mixture was cooled with ice, KHCO₃ (8 g) was added, and the resulting soln. evaporated. The residue was partitioned between H₂O and AcO(*i*-Pr). The org. phase was dried (Na₂SO₄) and evaporated. The oily residue (38 g) was purified by chromatography on silica gel, using cyclohexane/AcOEt 2:1. The fractions containing the product with *R*_f 0.56 (TLC, cyclohexane/AcOEt 1:1) were evaporated to give an oil. To a soln. of this residue (19.2 g) in 200 ml of toluene, PBr₃ (1.4 ml) was added dropwise below –10° over 10 min. Stirring was continued at r.t. After 2 h, 10% aq. KHCO₃ soln. was added to the mixture. The org. phase was dried (Na₂SO₄) and evaporated to give **14a** (14.5 g, 37% over 3 steps). M.p. 50–53°. ¹H-NMR: 3.18 (m, 2 H); 3.75 (s, 3 H); 4.48 (s, 2 H); 4.7 (m, 1 H); 5.1 (s, 2 H); 5.3 (d, *J* = 10, 1 H); 7.15 (s, 2 H); 7.38–7.55 (m, 10 H).

(*S*)-Methyl 2-[(Benzyloxycarbonyl)amino]-3-[5-(bromomethyl)-1,1'-biphenyl-3-yl]propanoate (**14b**). As described for **14a** with 1.4 g of **13b**, 4M aq. HCl (3.8 ml), MeOH (12 ml), and PBr₃ (0.25 ml): 0.9 g (71% over 3 steps) of **14b**. Oil. ¹H-NMR: 3.2 (m, 2 H); 3.75 (s, 3 H); 4.5 (s, 2 H); 4.7 (m, 1 H); 5.1 (s, 2 H); 5.3 (m, 1 H); 7.3 (s, 2 H); 7.3–7.6 (m, 11 H).

(*S*)-Methyl 2-[(Benzyloxycarbonyl)amino]-3-[2'-chloro-5-[(dimethoxyphosphino)yl]methyl]-1,1'-biphenyl-3-yl]propanoate (**15a**). A soln. of HPO(OMe)₂ (1.75 ml, 19.0 mmol) in abs. toluene (35 ml) was treated at r.t. with KN(SiMe₃)₂ (23.6 ml of 15% soln. in toluene; 15.6 mmol). Stirring was continued at r.t. After 20 min, the mixture was cooled to 0° and treated with a soln. of **14a** (3.35 g, 6.5 mmol) and 18-crown-6 (0.14 g) in toluene (30 ml). The

mixture was stirred at 0° for 1 h and hydrolyzed with sat. aq. NH₄Cl soln. The aq. phase was extracted with toluene. The org. layer was dried (Na₂SO₄) and evaporated. The oily residue (3.9 g) was purified by chromatography (silica gel, AcOEt/cyclohexane 1:1). The fractions containing the product of *R_f* 0.34 (TLC, AcOEt) yielded **15a** (2.8 g, 78%). ¹H-NMR: 3.15 (*d*, *J* = 21, 2 H); 3.18 (*m*, 2 H); 3.65 (*dd*, *J* = 8, 4, 6 H); 3.75 (*s*, 3 H); 4.7 (*m*, 1 H); 5.1 (*s*, 2 H); 5.33 (*d*, *J* = 10, 1 H); 7.3 (*s*, 5 H); 7.32 (*m*, 6 H); 7.45 (*m*, 1 H).

(*S*)-Methyl 2-[(Benzyloxycarbonyl)amino]-3-[5-[(dimethoxyphosphinoyl)methyl]-1,1'-biphenyl-3-yl]propanoate (**15b**). As described for **15a** with HPO(OBu)₂ (1.35 ml, 6.9 mmol) in abs. toluene (4 ml), KN(SiMe₃)₂ (11.8 ml of 15% soln. in toluene, 7.8 mmol), 18-crown-6 (70 mg), and **14b** (0.96 g, 2.0 mmol) in abs. toluene (2 ml): 0.3 g (25%) of **15b**. *R_f* 0.36 (TLC, AcOEt/cyclohexane 1:1). ¹H-NMR: 0.9 (*t*, *J* = 6, 6 H); 1.4 (*m*, 4 H); 1.65 (*m*, 4 H); 3.15 (*m*, 4 H); 3.95 (*s*, 3 H); 4.0 (*dt*, *J* = 7, 6, 4 H); 4.7 (*m*, 1 H); 5.1 (*s*, 2 H); 5.33 (*d*, *J* = 10, 1 H); 7.2–7.4 (*m*, 11 H); 7.5 (*m*, 2 H).

(*S*)-2-Amino-3-[2'-chloro-5-(phosphonomethyl)-1,1'-biphenyl-3-yl]propanoic Acid (**1a**) A soln. of **15a** (2.0 g, 36 mmol) in AcOH (38 ml) and 24% aq. HBr (33 ml) was stirred at ca. 65° for 72 h. About half of the solvent was evaporated *in vacuo*, and the pH was adjusted to 2 with conc. aq. NH₃. The amorphous product was filtered off. A soln. of this product in H₂O (25 ml) and conc. aq. NH₃ (0.5 ml) was added dropwise at 60° under stirring to 1M aq. HCl (4 ml) and THF (3 ml). Stirring was continued for 30 min at 60° and then at r.t. After 1 h, the crystals formed were filtered off and washed with H₂O: 1.03 g (76%; 97.8% ee) of (*S*)-**1a**, identical (m.p., TLC, [α]_D, ¹H-NMR) to the product obtained by the former synthetic pathway [1].

(*S*)-2-Amino-3-[5-(phosphonomethyl)-1,1'-biphenyl-3-yl]propanoic Acid (**1b**). As described for (*S*)-**1a** with 0.24 g (0.4 mmol) of **15b**: (*S*)-**1b** (0.08 g, 59%), identical (m.p., TLC, [α]_D, ¹H-NMR) to the product obtained by the former synthetic pathway [1].

We thank Mrs. J. Hohler for excellent technical assistance.

REFERENCES

- [1] W. Müller, P. Kipfer, D. A. Lowe, S. Urwyler, *Helv. Chim. Acta* **1995**, *78*, 2026.
- [2] S. Urwyler, D. Laurie, D. A. Lowe, C. L. Meier, W. Müller, *Neuropharmacology* **1996**, *35*, 643.
- [3] S. Urwyler, E. Campbell, G. Fricker, P. Jenner, M. Lemaire, K. H. McAllister, H. C. Neijt, C. K. Park, M. Perkins, M. Rudin, A. Sauter, L. Smith, K. H. Wiederhold, W. Müller, *Neuropharmacology* **1996**, *35*, 655.
- [4] R. Fitzi, D. Seebach, *Angew. Chem.* **1986**, *98*, 363; *ibid.*, *Int. Ed. Engl.* **1986**, *98*, 842; R. Fitzi, D. Seebach, *Tetrahedron* **1988**, *44*, 5277; D. Seebach, E. Dziadulewicz, L. Berendt, S. Cantoreggi, R. Fitzi, *Liebigs Ann. Chem.* **1989**, 1215.
- [5] S. Cacchi, P. G. Ciattini, E. Morera, G. Ortar, *Tetrahedron Lett.* **1986**, 5541.
- [6] J. M. Saá, M. Dopico, G. Martorell, A. Garcia-Raso, *J. Org. Chem.* **1990**, *55*, 991.
- [7] M. Atkinson, D. Hartley, L. H. C. Lunts, A. C. Ritchie, *J. Med. Chem.* **1974**, *17*, 248.

Received December 12, 1997